公开(公告)号：US10722572B2

公开(公告)日：2020-07-28

申请号：US16708787

申请日：2019-12-10

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

发明人： Yves Levy ,  Gerard Zurawski ,  Sandra Zurawski ,  Anne-Laure Flamar

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K39/12 ,  A61K39/21 ,  C07K14/005 ,  C12N7/00 ,  C07K16/10 ,  A61P31/18

摘要： Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

公开(公告)号：US11219683B2

公开(公告)日：2022-01-11

申请号：US16946390

申请日：2020-06-19

申请人： INSERM (Institut National de la Santé et de la Recherche Mêdicale) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

发明人： Yves Levy ,  Gerard Zurawski ,  Sandra Zurawski ,  Anne-Laure Flamar

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61P31/18 ,  C07K14/005 ,  C12N7/00 ,  C07K16/28 ,  C07K16/10

摘要： Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

公开(公告)号：US20190184008A1

公开(公告)日：2019-06-20

申请号：US16141157

申请日：2018-09-25

申请人： INSERM (Institut National de la Santé et de la Recherche Mêdicale ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

发明人： Yves Levy ,  Gerard Zurawski ,  Sandra Zurawski ,  Anne-Laure Flamar

IPC分类号： A61K39/21 ,  C07K16/28 ,  A61P31/18 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K2039/505 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6056 ,  A61K2039/627 ,  A61P31/18 ,  C07K14/005 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2319/02 ,  C07K2319/40 ,  C12N7/00 ,  C12N2740/16134 ,  C12N2740/16171

摘要： Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

公开(公告)号：US11957734B2

公开(公告)日：2024-04-16

申请号：US17301123

申请日：2021-03-25

申请人： BAYLOR RESEARCH INSTITUTE

发明人： SangKon Oh ,  Sandra Zurawski ,  Hyemee Joo ,  Gerard Zurawski

IPC分类号： A61K38/20 ,  A61K39/00 ,  C07K14/54 ,  C07K16/28

CPC分类号： A61K38/2066 ,  A61K39/0008 ,  C07K14/5428 ,  C07K16/2851 ,  C07K16/2878 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/57 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2319/00

摘要： Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.

公开(公告)号：US20220340670A1

公开(公告)日：2022-10-27

申请号：US17687971

申请日：2022-03-07

申请人： BAYLOR RESEARCH INSTITUTE

发明人： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC分类号： C07K16/28 ,  C07K14/005

摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US10286058B2

公开(公告)日：2019-05-14

申请号：US15111357

申请日：2015-01-13

申请人： BAYLOR RESEARCH INSTITUTE

发明人： SangKon Oh ,  Sandra Zurawski ,  Gerard Zurawski

IPC分类号： A61K39/12 ,  A61K39/395 ,  C07K14/025 ,  C07K16/28 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

摘要： Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20160031988A1

公开(公告)日：2016-02-04

申请号：US14887151

申请日：2015-10-19

申请人： BAYLOR RESEARCH INSTITUTE

发明人： Gerard Zurawski ,  Anne-Laure Flamar ,  Eynav Klechevsky

IPC分类号： C07K16/28 ,  A61K39/44

CPC分类号： C07K16/28 ,  A61K39/44 ,  C07K14/33 ,  C07K16/00 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2319/00 ,  C07K2319/33

摘要： The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.

摘要翻译： 本发明包括用于设计，制造和使用模块化重组抗体或其片段的组合物和方法，所述重组抗体或其片段具有允许多变抗原缀合物的快速装配的粘稠素 - 停泊聚糖对的一半。

公开(公告)号：US20150299329A1

公开(公告)日：2015-10-22

申请号：US14610456

申请日：2015-01-30

申请人： BAYLOR RESEARCH INSTITUTE

发明人： Gerard Zurawski ,  Jacques F. Banchereau ,  Anne-Laure Flamar ,  Yves Levy ,  Monica Montes

IPC分类号： C07K16/28 ,  C07K16/00 ,  C07K14/005

CPC分类号： C07K16/2878 ,  A61K39/00 ,  A61K39/385 ,  A61K2039/6056 ,  A61K2039/627 ,  A61K2039/64 ,  C07K14/005 ,  C07K16/00 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/77 ,  C07K2317/80 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2740/16222 ,  C12N2740/16322 ,  C12N2760/16122 ,  C12N2770/24222 ,  C12N2770/24234 ,  G01N33/6863 ,  Y02A50/39 ,  Y02A50/464 ,  Y02A50/466

摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

摘要翻译： 本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。 在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗-CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。

公开(公告)号：US20150064205A1

公开(公告)日：2015-03-05

申请号：US14484599

申请日：2014-09-12

申请人： BAYLOR RESEARCH INSTITUTE

发明人： SangKon Oh ,  Jacques F. Banchereau ,  Gerard Zurawski ,  Hideki Ueno ,  Ling Ni

IPC分类号： C07K16/28 ,  A61K47/42 ,  A61K47/36

CPC分类号： C07K16/2851 ,  A61K39/12 ,  A61K39/145 ,  A61K39/385 ,  A61K39/39 ,  A61K47/36 ,  A61K47/42 ,  A61K2039/55572 ,  A61K2039/6056 ,  C07K2317/76 ,  C07K2319/035 ,  C12N2760/16134

摘要： Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections.

摘要翻译： 本文公开了用于增强Th1 / Th17细胞应答和降低Th2细胞应答的组合物和方法。 在各种实施方案中，本发明描述了在含有Dectin-1的人树状细胞中激活人树突状细胞的活化和增强抗原特异性T细胞应答，所述树突细胞包含与一种或多种抗原融合的抗Dectin-1特异性抗体或其片段 。 还可以包括TLR2配体以增强T细胞反应的活化和增强。 此外，本发明还包括基于本文所述的用于治疗病原体感染的组合物的方法。

公开(公告)号：US20140227268A1

公开(公告)日：2014-08-14

申请号：US14254206

申请日：2014-04-16

申请人： Baylor Research Institute

发明人： Jacques F. Banchereau ,  Sangkon Oh ,  Gerard Zurawski ,  Sandra Zurawski ,  Dapeng Li

IPC分类号： C07K16/28 ,  C07K14/435 ,  C07K14/37 ,  C07K14/405 ,  C07K14/005 ,  C07K14/195

CPC分类号： A61K39/145 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/5154 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C12N5/0639 ,  C12N7/00 ,  C12N2760/16122 ,  C12N2760/16134 ,  Y02A50/472

摘要： The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

摘要翻译： 本发明包括用于制备和使用可以例如激活DC和其他细胞的抗DC-ASGPR抗体的组合物和方法。